Author of

• 31322

  +

  P2.11 - Screening and Early Detection (ID 178)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Screening and Early Detection
  • Presentations: 1
  • Now Available
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 32090

    +

    P2.11-28 - Late-Breaking Abstract - Clinical Potential of Sputum Hyaluronan Measurement in the Diagnosis and Prognosis of Patients with NSCLC (Now Available) (ID 2622)

    10:15 - 18:15  |  Author(s): Milena Shizue Tariki
    • Abstract
    • Slides

    Background
    

    Lung cancer is the most frequently diagnosed and also the most lethal due to late diagnosis. Many efforts are being made to mitigate this problem. In this scenario, sputum is a potentially attractive source of biomarkers present in the extracellular matrix such as hyaluronan (HA). The aim of this study is to validate HA levels in sputum’s patients with non-small cell lung cancer (NSCLC) at the time of diagnosis and after first-line treatment evaluation response and correlate the values response rate in patients submitted to definitive treatment with chemotherapy and/or radiotherapy, progression and recurrence. We also evaluated the HA concentrations in chronic obstructive pulmonary Disease (COPD) and healthy volunteers and its impact on the screening and diagnosis of lung cancer patients.

    Method
    

    HA was examined in sputum samples of 64 NSCLC, 14 COPD patients and 15 healthy controls. All the patients and healthy controls selected underwent a sputum induction.The levels of HA were measured in ng/ug of protein by a noncompetitive ELISA-like fluorometric assay.

    Result
    

    A significant different concentration pattern of HA in the sputum was found among NSCLC (median: 33.25 ng/mg), COPD (median:16.6ng/ug) and healthy individuals (median: 12.2 ng/ug), (p<0.001, Fig. 1A), as well as NSCLC before first-line treatment (median:33.25ng/mg) and after 6 months treatment regimens with good response (median:6.2ng/ug), (p<0.001, Fig 2).

    Conclusion
    

    Based on the results obtained so far, we rely on the clinical potential of sputum as a screening tool in the early detection of lung cancer.
    
    Fig. 1A
    
    
    Fig. 2
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.